Aktuellt
SENASTE
With the new CEO in place, Simris has now set course to pursue the most high value application area for microalgae, the biopharma sector in general and the novel Antibody Drug Conjugate (ADC) market for cancer treatment in particular. With revenue opportunities in the form of collaborations with pharma companies, alongside of the algae biomass and food supplement businesses already in scale-up phase, the venture into biopharma has potential to dominate the business in the long-term, adding to the potential triggers to unlock a revaluation of the share.
LÄS MER
